Articles

November 30, 2023 Alnylam Named #1 Largest Employer in MA for 3rd Year in a Row by The Boston Globe Alnylam has been named the #1 Largest Employer in MA for the 3rd year in a row and a Top Place to Work for the 9th year in a row. Read More ›
October 26, 2023 Alnylam Named a Top Science Employer by Science Magazine for the 5th Year in a Row Alnylam has been named a Science Magazine Top Employer for the 5th year in a row. Read More ›
August 15, 2023 Alnylam Named a Humankind 100 Company for the Second Year in a Row Alnylam has been named to the HumanKind 100 list for the 2nd year in a row and we’re pleased to have moved up in the rankings from #97 in 2022 to #76 in 2023. Read More ›
July 24, 2023 Alnylam Named a Best Workplace for Millennials for 2023 by Fortune and Great Place to Work Alnylam is ranked #19 on Fortune and Great Place to Work's 2023 list of Best Workplaces for Millennials. Read More ›
July 11, 2023 Alnylam Named a Best Workplace for Innovators for the 3rd Year in a Row by Fast Company Alnylam has been named a Fast Company Best Workplace for Innovators for 2023, our 3rd year in a row. Read More ›
June 23, 2023 Alnylam in the Community: CASPAR Partnership Highlight Alnylam has partnered with community organization CASPAR (Cambridge And Somerville Programs for Addiction Recovery) for many years. Read More ›
May 3, 2023 Building a Corporate Responsibility Program from the Ground Up: Key Learnings from Alnylam ... If you are building your program or assessing your program, here are five key learnings which may be helpful to your organization Read More ›
April 24, 2023 2022 Annual Report: CEO Yvonne Greenstreet Reflects on the Next Chapter in the RNAi Revolu ... Alnylam CEO Yvonne Greenstreet reflects on the company's accomplishments in 2022 and highlights of the 2022 annual report. Read More ›
March 29, 2023 Leading by Example in Gender Diversity Among Executive Leadership Alnylam ranked #1 among MA public companies in board of directors gender diversity and #3 in executive leadership gender diversity in the 2023 WPG report.   Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site